NCT Number: NCT01460836
Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis
Matching-adjusted indirect comparison of tobramycin solution (TIS) versus aztreonam lysine (AZLI) using TIS patient level clinical trial data and AZLI aggregated clinical trial data from published literature.
Looking for future studies?
Notify MeKey information
Conditions
Age range
6 year and older
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- ≥ 6 years of age with a documented Cystic fibrosis (CF) diagnosis,
- moderate-to severe lung disease,
- the ability to perform reproducible pulmonary function tests,
- Pseudomonas aeruginosa (PA) airway infection.
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply.
Treatment and study plan
Aztreonam lysine for inhalation
DrugPrimary outcomes
-
Mean relative change in Forced Expiratory Volume in 1 second (FEV1) from baseline
Time frame: Baseline, Weeks 2, 4 and 6
Secondary outcomes
-
Mean change in the density of Pseudomonas aeruginosa (PA) from baseline
Time frame: Baseline, Weeks 2, 4 and 6
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Novartis Pharmaceuticals
Industry
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2010
- First posted
- Oct 27, 2011
- Registry last updated
- Oct 27, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
NCT03489629
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Denver, Colorado, United States
View Trial DetailsEvaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients
NCT04994301
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Indianapolis, Indiana, United States
View Trial DetailsComparison of Physical Activity, Exercise Capacity, Quality of Life, Cognitive Function and Coronavirus Phobia Levels of Adult Cystic Fibrosis Patients With Healthy Individuals With Telerehabilitation
NCT04673331
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Ankara, Turkey (Türkiye)
View Trial DetailsSildenafil Exercise: Role of PDE5 Inhibition
NCT04039087
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Denver, Colorado, United States
View Trial Details